

Vicore Pharma - Positioned for the Top

Redeye updates its view on Vicore following an eventful year for the company and its increasingly compelling pipeline. We raise our Base Case to SEK 75 (64) per share largely thanks to progressively strong data for lead project C21 in IPF and adjust the rest of our sum-of-the-parts valuation owing to our mounting confidence in its pipeline.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Vicore Pharma - Positioned for the Top